SPARC Grants | Priorities and Goals | Application information | Mentorship and Support | Selection Advisory Group | 2015 Awardees


There are four major priorities within the SPARC Grants, and applicants may choose to address one.

  • Patient Navigation and Communication: Developing health information and/or support services specifically adapted for advanced breast cancer patients. The purpose will be to improve the patient’s ability to navigate diagnosis, treatment, care, and/or palliation (depending on the needs in your setting). Additional elements may pertain to: improving communication between health professionals and patients, informed or shared decision-making, understanding the role of clinical trials, and/or social support needed for both patients and their loved ones. 
  • Raising Patient Voices: Amplifying the patient’s voice in health systems and wider society. The purpose will be to reduce stigma and increase public awareness of the patient’s perspective, and to develop specific projects that can lead to cost-effective improvements in survival, quality of life, and add productive years to families and society and decrease the rate of metastatic disease at diagnosis. 
  • National Planning and Policy:Improving the national response to the diagnosis and management of advanced breast cancer. The purpose will be to provide planners and policy-makers with guidance on the unique challenges of metastatic disease, including the patient’s perspective, and how to address these challenges in the National Cancer Control Plan. Additional elements may pertain to: resource-adapted management guidelines, necessity of early introduction to supportive and palliative care, and ensuring equitable access to timely and appropriate care, for example widespread access to WHO essential medicines and devices.
  • Earlier Presentation: Decreasing the incidence rate of de novo advanced breast cancer. The purpose will be to improve strategies to encourage women to visit a doctor and access timely treatment to decrease the incidence of locally advanced and metastatic disease at first diagnosis (i.e. de novo disease). This could be achieved in many creative ways depending on the context however we do not encourage projects on screening.

It is the primary objective of Pfizer and the UICC to empower women living with advanced breast cancer to lead productive lives with a high quality of life at the patient level, the local level, and the systems level, and to strive to reduce the incidence of de novo advanced disease. Organizations that propose new programs or to meet new goals will be considered; (funding is not available for projects already being run by an organization).  

Faced with such a massive burden of disease globally, we must better understand response methods, metrics and evaluation of success, transferability, and sustainability. Thus, the core granting priority is impact – the ways in which the proposed program or initiative will not only fill gaps in the cascade or services and wraparound services but also how gains will be measured and maintained. Thus, an applicant’s ability to demonstrate or explain how their initiative will create lasting change is a central focus of the selection criteria. Furthermore, an applicants ability to explain how that change will be maintained over time will also be evaluated. Preference may be given to those organizations that can provide examples of how they have implemented impactful programs in the past, measured outcomes, and sustained progress over time.